Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis

"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."

One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.

"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."

"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."